International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib

---

Autoria(s): Deininger, Michael; O’Brien, Stephen G.; Guilhot, Francois; Goldman, John M.; Hochhaus, Andreas; Hughes, Timothy P.; Radich, Jerald P.; Hatfield, Alan K.; Mone, Manisha; Filian, Jeiry; Reynolds, John; Gathmann, Insa; Larson, Richard A.; Druker, Brian J.

Data(s)	20/11/2009
Identificador	http://hdl.handle.net/10536/DRO/DU:30060086
Idioma(s)	eng
Publicador	American Society of Hematology
Relação	http://dro.deakin.edu.au/eserv/DU:30060086/reynolds-internationalrandomizedstudy-2009.pdf http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/1126?maxtoshow=
Palavras-Chave	#international randomized study (IRIS) #interferon #STI571 #8-year follow-up #sustained survival #low risk for progression #patients #newly diagnosed #chronic myeloid leukemia in chronic phase (CML-CP) #imatinib
Tipo	Journal Article